ReviewBMC pediatrics2025
Rubinstein-Taybi syndrome with ganglioneuroblastoma: a case report and literature review.
Review in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundRubinstein-Taybi syndrome (RSTS) is a rare genetic disorder characterized by severe global developmental delay (GDD) and distinctive facial grimacing. The loss of function of the CREBBP and EP300 genes is recognized as a genetic etiology of RSTS. However, the association between CREBBP variants and an increased risk of tumors remains unknown, despite multiple reports of tumor comorbidities related to RSTS. The aim of this study is to elucidate the tumors associated with CREBBP variants in the context of RSTS by presenting a case of ganglioneuroblastoma (GNB) in a patient diagnosed with RSTS. CASE PRESENTATION: We describe a 9-month-old male patient exhibiting distinctive facial features, enorchia, and GDD. Whole exome sequencing (WES) revealed a de novo pathogenic variant in NM_004380 (CREBBP): c.1068del (p.Gln356Hisfs*33). At one year of age, the patient experienced an unexplained fever lasting for two months, and the definitive diagnosis of GNB was established.
conclusionsWe report a case of RSTS co-morbid with GNB and conduct phenotypic and genotypic analyses of 43 individuals with documented CREBBP variants and associated tumors in the literature. We observed that frameshift variations are common in malignancies among the individuals studied, while more microdeletions were noted in patients with benign tumors. Currently, there is insufficient evidence to support a correlation between the types of CREBBP variants and specific tumor types. Further research is required to clarify the role of CREBBP variants in tumorigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.